These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17130190)

  • 21. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study.
    Lacourcière Y; Wright JT; Samuel R; Zappe D; Purkayastha D; Black HR;
    Blood Press Monit; 2009 Jun; 14(3):112-20. PubMed ID: 19384192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.
    Calhoun DA; Glazer RD; Pettyjohn FS; Coenen PD; Zhao Y; Grosso A
    Curr Med Res Opin; 2008 Aug; 24(8):2303-11. PubMed ID: 18593517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
    ; Dagenais GR; Gerstein HC; Holman R; Budaj A; Escalante A; Hedner T; Keltai M; Lonn E; McFarlane S; McQueen M; Teo K; Sheridan P; Bosch J; Pogue J; Yusuf S
    Diabetes Care; 2008 May; 31(5):1007-14. PubMed ID: 18268075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertension.
    Gleim GW; Rubino J; Zhang H; Shahinfar S; Soffer BA; Lyle PA; Littlejohn TW; Feig PU
    Clin Ther; 2006 Oct; 28(10):1639-48. PubMed ID: 17157119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes.
    Cnop M; Vidal J; Hull RL; Utzschneider KM; Carr DB; Schraw T; Scherer PE; Boyko EJ; Fujimoto WY; Kahn SE
    Diabetes Care; 2007 Mar; 30(3):677-82. PubMed ID: 17327340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Telmisartan improves vascular function independently of metabolic and antihypertensive effects in hypertensive subjects with impaired glucose tolerance.
    Perl S; Schmölzer I; Sourij H; Pressl H; Eder M; Zweiker R; Wascher TC
    Int J Cardiol; 2010 Mar; 139(3):289-96. PubMed ID: 19118910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of glucose intolerance in patients with chronic hepatitis B or C: a prospective case-control study.
    Mavrogiannaki A; Karamanos B; Manesis EK; Papatheodoridis GV; Koskinas J; Archimandritis AJ
    J Viral Hepat; 2009 Jun; 16(6):430-6. PubMed ID: 19200136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
    Cooper-Dehoff R; Cohen JD; Bakris GL; Messerli FH; Erdine S; Hewkin AC; Kupfer S; Pepine CJ;
    Am J Cardiol; 2006 Oct; 98(7):890-4. PubMed ID: 16996868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.
    Bakris G; Hester A; Weber M; Dahlof B; Pitt B; Velasquez E; Staikos-Byrne L; Shi V; Jamerson K;
    J Cardiometab Syndr; 2008; 3(4):229-33. PubMed ID: 19040592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diabetes and impaired glucose tolerance prevalences in Turkish patients with impaired fasting glucose.
    Tutuncuoğlu P; Saraç F; Saygili F; Ozgen AG; Yilmaz C; Tüzün M
    Acta Diabetol; 2008 Sep; 45(3):151-6. PubMed ID: 18496644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
    Shi Y; Guo M; Yan J; Sun W; Zhang X; Geng L; Xu L; Chen Z
    Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic characteristics of soleus muscle in relation to insulin action in the offspring of hypertensive parents.
    Kratochvílová S; Vyhnanovská P; Vlasáková Z; Hájek M; Skibová J; Pelikánová T
    Metabolism; 2006 Oct; 55(10):1388-96. PubMed ID: 16979411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lifestyle intervention in individuals with normal versus impaired glucose tolerance.
    Schäfer S; Kantartzis K; Machann J; Venter C; Niess A; Schick F; Machicao F; Häring HU; Fritsche A; Stefan N
    Eur J Clin Invest; 2007 Jul; 37(7):535-43. PubMed ID: 17576204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Usefulness of oral glucose tolerance test (OGTT) in output patients with advanced chronic renal failure (CRF)].
    Rufino M; Barbero P; Hernández D; Torres A; Lorenzo V
    Nefrologia; 2007; 27(1):30-7. PubMed ID: 17402877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial.
    Hermida RC; Ayala DE; Khder Y; Calvo C
    Clin Ther; 2008 Jan; 30(1):108-20. PubMed ID: 18343247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial.
    Aksnes TA; Kjeldsen SE; Rostrup M; Störset O; Hua TA; Julius S
    J Hum Hypertens; 2008 Aug; 22(8):520-7. PubMed ID: 18509347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of 3-year lifestyle intervention on postprandial glucose metabolism: the SLIM study.
    Roumen C; Corpeleijn E; Feskens EJ; Mensink M; Saris WH; Blaak EE
    Diabet Med; 2008 May; 25(5):597-605. PubMed ID: 18445174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of a fixed-dose combination of trandolapril-verapamil in obese hypertensive patients resistant to monotherapy.
    Rubio-Guerra AF; Lozano-Nuevo JJ; Vargas-Ayala G; Rodríguez-López L; Ramos-Brizuela LM; Escalante-Acosta BA
    Clin Exp Hypertens; 2006 Oct; 28(7):619-24. PubMed ID: 17060060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnosis of impaired glucose tolerance in hypertensive patients in daily clinical practice.
    Lüders S; Hammersen F; Kulschewski A; Venneklaas U; Züchner C; Gansz A; Schnieders M; Pfarr E; Sturm CD; Paar WD; Schrader J
    Int J Clin Pract; 2005 Jun; 59(6):632-8. PubMed ID: 15924589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.